Literature DB >> 8889455

Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

D S Bansi1, R W Chapman, K A Fleming.   

Abstract

BACKGROUND: Antineutrophil cytoplasmic antibodies (ANCA) are of proven diagnostic value in a variety of vasculitides, where they are also thought to play a pathogenic role. ANCA has also been detected in the serum of patients with idiopathic inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD), and primary sclerosing cholangitis (PSC) with or without concomitant IBD. Although the prevalence in PSC and UC is reported to be up to 85%, a much lower prevalence of around 10-20% has been reported in CD. AIM: To determine ANCA prevalence in a group of British patients with IBD and evaluate their use as a serological marker to distinguish between UC and CD.
METHODS: A total of 99 UC-only patients (44 males, median age 50) and 41 CD patients (11 males, median age 47) were tested for ANCA using an alkaline phosphatase technique at a 1:5 serum dilution. Controls were other diarrhoeal diseases including 17 coeliac disease (4 males, median age 41), 23 irritable bowel syndrome (5 males, median age 42), 5 infectious colitis (2 male, median age 64) and 36 healthy volunteers (13 males, median age 43).
RESULTS: ANCA was detected in 42/99 (42.4%) UC patients but in only 2/41 (5%) CD (P < 0.0001). All ANCA were perinuclear in distribution. No ANCA was detected in the control sera. The sensitivity of the test for the diagnosis of UC was 42% with a specificity of 98%. In patients with UC, no association was found between presence of ANCA and age, sex, disease extent, treatment or activity. However, ANCA-positive UC patients had longer median duration of disease (50 months vs. 29 months, P = 0.037). Both CD ANCA-positive patients had colonic involvement, but one also had ileal disease. Both had inactive disease and one was on mesalazine.
CONCLUSIONS: ANCA is highly specific for UC and may be a helpful diagnostic test in distinguishing UC from CD and other diarrhoeal illnesses. Although ANCA positivity may reflect disease heterogeneity within UC, no association with clinical features or treatment of UC was demonstrated and it is therefore unlikely to play a pathogenic role. The correlation with disease duration needs further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889455

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

4.  Ulcerative colitis and perinuclear antineutrophil cytoplasmic antibodies.

Authors:  P C Doré
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

5.  Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-06

6.  Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis.

Authors:  Yanhua Pang; Huijie Ruan; Dongfang Wu; Yanfei Lang; Ke Sun; Cuiping Xu
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-20       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.